Cutting edge: Systemic inhibition of angiogenesis underlies resistance to tumors during acute toxoplasmosis

Journal of Immunology

Volumn 166, Issue 10, 2001, Pages 5878-5881

  Hunter, Christopher A ^a   Yu, Duonan ^a   Gee, Michael ^a   Ngo, Cam V ^a   Sevignani, Cinzia ^a   Goldschmidt, Michael ^a   Golovkina, Tatyana V ^b   Evans, Sydney ^a   Lee, William F ^a   Thomas Tikhonenko, Andrei ^a  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b JACKSON LABORATORY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOGENESIS; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; AVASCULAR NECROSIS; CANCER INHIBITION; CELLULAR IMMUNITY; CONTROLLED STUDY; HYPOXIA; IMMUNE RESPONSE; IMMUNOSTIMULATION; MOUSE; NEOVASCULARIZATION (PATHOLOGY); NONHUMAN; PRIORITY JOURNAL; TOXOPLASMA GONDII; TOXOPLASMOSIS; TUMOR RESISTANCE;

EID: 0035873413     PISSN: 00221767     EISSN: None     Source Type: Journal    
DOI: 10.4049/jimmunol.166.10.5878     Document Type: Article

References (35)

1. Coley, W. B. 1991. The treatment of malignant tumors by repeated inoculations of erysipelas with a report of ten original cases: 1893 classical article. Clin. Orthopaedics Related Res. 262:3.
2. Hibbs, J. B. J. 1976. Role of activated macrophages in nonspecific resistance to neoplasia. J. Reticuloendothelial Soc. 20:223.
3. Youdim, S. 1977. Cooperation of immune lymphoid and reticuloendothelial cells during Listeria monocytogenes-mediated tumor immunity. Cancer Res. 37:991.
4. North, R. J., and D. P. Kirstein. 1977. T-cell-mediated concomitant immunity to syngeneic tumors. I. Activated macrophages as the expressors of nonspecific immunity to unrelated tumors and bacterial parasites J. Exp. Med. 145:275.
5. Keller, R., R. Keist, T. P. Leist, and, P. H. van der Meide. 1990. Resistance to a non-immunogenic tumor, induced by Corynebacterium parvum or Listeria monocytogenes, is abrogated by anti-interferon γ. Int. J. Cancer 46:687.
6. Paglia, P., and C. A. Guzman. 1998. Keeping the immune system alerted against cancer. Cancer Immunol. Immunother. 46:88.
7. Villegas, E. N., M. M. Elloso, G. Reichmann, R. Peach, and C. A. Hunter. 1999. Role of CD28 in the generation of effector and memory responses required lor resistance to Toxoplasma gondii. J. Immunol. 163:3344.
8. Ngo, C., M. S. Gee, N. Akhtar, D. Yu, O. V. Volpert, R. Auerbach, and A. Thomas-Tikhonenko. 2000. An in vivo function for the transforming myc protein: elicitation of the angiogenic phenotype. Cell Growth Differ. 11:201.
9. Lord, E. M., L. Harwell, and C. J. Koch. 1993. Detection of hypoxic cells by monoclonal antibody recognizing 2-nitroimidazole adducts. Cancer Res. 53:5721.
10. Thurston, G., P. Baluk, A. Hirata, and D. M. McDonald. 1996. Permeability-related changes revealed at endothelial cell borders in inllamed venules by lectin binding. Am. J. Physiol. 271:H2547.
11. Dranoff, G., E. Jaffee, A. Lazenby, P. Golumbek, H. Levitsky, K. Brose, V. Jackson, H. Hamada, D. Pardoll, and R. C. Mulligan. 1993. Vaccination with irradiated tumor cells engineered to secrete murine granulocyte-macrophage colony-stimulating factor stimulates potent, specific, and long-lasting anti-tumor immunity. Proc. Natl. Acad. Sci. USA 90:3539.
12. Sevignani, C., P. Wlodarski, J. Kirillova, W. E. Mercer, K. G. Danielson, R. V. Iozzo, and B. Calabretta. 1998. Tumorigenic conversion of p53-deficient colon epithelial cells by an activated Ki-ras gene. J. Clin. Invert. 101:1572.
13. McCoy, M. S., C. I. Bargmann, and R. A. Weinberg. 1984. Human colon carcinoma Ki-ras2 oncogene and its corresponding proto-oncogene. Mol. Cell. Biol. 4:1577.
14. Peace, D. J., W. Chen, H. Nelson, and M. A. Cheever. 1991. T cell recognition of transforming proteins encoded by mutated ras proto-oncogenes. J. Immunol. 146:2059.
15. Klostergaard, J. 1993. Macrophage tumoricidal mechanisms. Res. Immunol. 144:274.
16. Xie, K., and I. J. Fidler. 1998. Therapy of cancer metastasis by activation of the inducible nitric oxide synthase. Cancer Metastasis Rev. 17:55.
17. Klostergaard, J., M. E. Leroux, and M. C. Hung. 1991, Cellular models of macrophage tumoricidal effector mechanisms in vitro: characterization of cytolytic responses to tumor necrosis factor and nitric oxide pathways in vitro. J. Immunol. 147:2802.
18. Laubach, V. E., E. G. Shesely, O. Smithies, and P. A. Sherman. 1995. Mice lacking inducible nitric oxide synthase are not resistant to lipopolysaccharide-induced death. Proc. Natl. Acad. Sci. USA 92:10688.
19. Kagi, D., B. Ledermann, K. Burki, P. Seiler, B. Odermatt, K. J. Olsen, E. R. Podack, R. M. Zinkernagel, and H. Hengartner. 1994. Cytotoxicity mediated by T cells and natural killer cells is greatly impaired in perforin-deficient mice. Nature 369:31.
20. Magram, J., S. E. Connaughton, R. R. Warrier, D. M. Carvajal, C. Y. Wu, J. Ferrante, C. Stewart, U. Sarmiento, D. A. Faherty, and M. K. Gately. 1996, IL-12-deficient mice are defective in IFN γ production and type 1 cytokine responses. Immunity 4:471.
21. Pfeffer, K., T. Matsuyama, T. M. Kundig, A. Wakeham, K. Kishihara, A. Shahinian, K. Wiegmann, P. S. Ohashi, M. Kronke, and T. W. Mak. 1993. Mice deficient for the 55 kd tumor necrosis factor receptor are resistant to endotoxic shock, yet succumb to L. monucytogenes infection. Cell 73:457.
22. Rohan, R. M., A. Fernandez, T. Udagawa, J. Yuan, and R. J. D'Amato. 2000. Genetic heterogeneity of angiogenesis in mice. FASEB J. 14:871.
23. Evans, S. M., M. Bergeron, D. M. Ferriero, F. R. Sharp, H. Hermeking, R. N. Kitsis, D. L. Geenen, S. Bialik, E. M. Lord, and C. J. Koch. 1997. Imaging hypoxia in diseased tissues. Adv. Exp. Med. Biol. 428:595.
24. Gee, M. S., C. J. Koch, S. M. Evans, W. T. Jenkins, C. H. J. Pletcher, J. S. Moore, H. K. Koblish, J. Lee, E. M. Lord, G. Trinchieri, and W. M. Lee. 1999. Hypoxia-mediated apoptosis from angiogenesis inhibition underlies tumor control by recombinant interleukin 12. Cancer Res. 59:4882.
25. Algire, G. H., F. Y. Legallais, and H. D. Park. 1947. Vascular reactions of normal and malignant tissues in vivo. II. The vascular reaction of normal and neoplastic tissues of mice to a bacterial polysaccharide from Serratia marcescens (Bacillus prodigiosus) culture filtrates. J. Natl. Cancer Inst. 8:53.
26. Pepper, M. S., S. J. Mandriota, J. D. Vassalli, L. Orci, and R. Montesano. 1996. Angiogenesis-rogulating cytokines: activities and interactions. Curr. Top. Microbiol. Immunol. 213:31.
27. Ellis, L. M., and I. J. Fidler. 1996. Angiogenesis and metastasis. Eur. J. Cancer 32A:2451.
28. 3-, in the disruption of the tumor vasculature induced by TNF and IFN-γ. Nat. Med. 4:408.
29. Khan, I. A., J. A. MacLean, F. S. Lee, L. Casciotti, E. DeHaan, J. D. Schwartzman, and A. D. Luster. 2000. IP-10 is critical for effector T cell trafficking and host survival in Toxoplasma gondii infection. Immunity 12:483.
30. Strieter, R. M., S. L. Kunkel, D. A. Arenberg, M. D. Burdick, and P. J. Polverini. 1995. Interferon γ-inducible protein 10 (IP-10), a member of the C-X-C chemokine family, is an inhibitor of angiogenesis. Biochem. Biophys. Res. Commun. 210:51.
31. Ruskin, J., and J. S. Remington. 1976. Toxoplasmosis in the compromised host. Ann. Intern. Med. 84:193.
32. Boehm, T., J. Folkman, T. Browder, and M. S. O'Reilly. 1997. Antiangiogenic therapy of experimental cancer does not induce acquired drug resistance. Nature 390:404.
33. O'Reilly, M. S., T. Boehm, Y. Shing, N. Fukai, G. Vasios, W. S. Lane, E. Flynn, J. R. Birkhead, B. R. Olsen, and J. Folkman. 1997. Endostatin: an endogenous inhibitor of angiogenesis and lumor growth. Cell 88:277.
34. Voest, B. E., B. M. Kenyon, M. S. O'Reilly, G. Truitt, R. J. D'Amato, and J. Folkman. 1995. Inhibition of angiogenesis in vivo by interleukin 12. J. Natl. Cancer Inst. 87:581.
35. Coughlin, C. M., K. E. Salhany, M. Wysocka, E. Aruga, H. Kurzawa, A. E. Chang, C. A. Hunter, J. C. Fox, G. Trinchieri, and W. M. F. Lee. 1998. Interleukin-12 and interleukin-18 synergistically induce murine tumor regression which involves inhibition of angiogenesis. J Clin. Invest. 101:1441.